For Immediate Release
Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, President and Representative Director
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Noriaki Ishida, General Manager,
Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com/
Daiichi Sankyo Equity Transfer for Shanghai Xinshengyuan Pharmaceutical Group Medicine & Chemical Reagents Sales Co., Ltd. in China
Tokyo, Japan (April20, 2012) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that its 100 percent owned China subsidiary, Daiichi Sankyo (China) Holdings, Co., Ltd. (hereafter, Daiichi Sankyo China), came to an agreement with Shanghai Xinshengyuan Pharmaceutical (Group) Co., Ltd. (hereafter, Xinshengyuan Group)to receive all equity owned by Shanghai Xinshengyuan Pharmaceutical Group Medicine & Chemical Reagents Sales Co., Ltd. (hereafter, Xinshengyuan), the 100 percent owned subsidiary of Xinshengyuan Group. The matter has been registered with the appropriate Chinese authorities.
Daiichi Sankyo established Daiichi Sankyo China in November 2011 for the purpose of advancing its strategic investment in China. With this agreement, all of the equity of Xinshengyuan will be transferred to a wholly-owned subsidiary of Daiichi Sankyo China.
By adding Xinshengyuan into the Group, Daiichi Sankyo will be able to import and market Ranbaxy products to China in addition to its own product lines. Furthermore, by adding innovative pharmaceuticals, including other company’s products, to generic pharmaceuticals in the future, Daiichi Sankyo aims to further grow its business in China.
● Overview of DAIICHI SANKYO (CHINA) HOLDINGS CO., LTD.
Date of establishment: November 8, 2011
Business: Management of Chinese subsidiary business and investment
Capital: USD $30 million
Employees: Approximately 40 (as of April, 2012)
Location: Shanghai, China
● Overview of Xinshengyuan
Date of establishment: December 2002
Business: Import and sale of pharmaceuticals
Capital: 25 million RMB
Location: Shanghai, China
End